Recombinetics provides gene editing solutions for biomedical research, regenerative medicine, and animal agriculture. The company utilizes its proprietary gene editing platform to develop technologies that impact human health and enhance farm animal value.

Recombinetics

Hera BioLabs provides preclinical research services with a focus on gene editing. The company offers proprietary platforms and custom research models to support drug discovery and development.

Hera BioLabs

Pairwise focuses on the application of CRISPR technology in food and agriculture, delivering unique varieties of crops for growers and consumers.

Tom Adams

Haven Baker

Pairwise

Recombinetics is involved in animal gene editing and associated technologies for biomedical research, regenerative medicine, and animal agriculture, self-described as a leader in these fields.

Recombinetics  | 2,157 followers on LinkedIn. Delivering the Next Evolution of Healthcare

 | Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture.

Led by a team of expert geneticists, genome engineers, and reproductive physiologists, the company is headquartered in St.

Legal and HR Manager at Recombinetics

Nikki Rockstroh, MnCP

Experienced General Counsel & Corporate Secretary | JD, Six Sigma

John Burtis

CFO RCI

Justin Zenanko

Quality Control Supervisor at Recombinetics, Inc.

Ashley Lokensgard

Beta testers wanted: Recombinetics is looking for users of iPSCs to help test our cells and robust growth media. Would your research benefit from the availability of Porcine Pluripotent Stem Cells? At Recombinetics we specialize in gene editing, animal reproduction, and cell manufacturing. With this we have derived and characterized both porcine induced pluripotent and embryonic stem cell lines that are stable for well over 60 passages and counting. We are seeking a handful of beta testers to evaluate how the cells perform in different labs and applications. If this is something you are interested in or would like more information, please contact info@Recombinetics.com or see our website at www.Recombienetics.com #betatest #iPSCs #geneediting #regenativemedicine #stemcells

We’re in Baltimore for ASGCT 2024! Stop by poster #517 on Wednesday, May 8th at 5:30 EST to hear from Jarryd Campbell about our swine reporter models for somatic cell genome editing. We are looking forward to making some new connections and meeting up with old colleagues. #asgct #pigmodel #geneediting

Gene therapy continues to advance healthcare…

Recombinetics is excited to share the work our subsidiary, @Acceligen, has put together. Check out the note in the National Hog Farmer on the work done to generate PRRS resistant pigs. Porcine Respiratory and Reproductive Syndrome (PRRS) is a constant concern for pork production. The scientific information can be found in our paper published in collaboration with Rowland, Robert in the journal of Antiviral Research.

Metric
Company Name	Recombinetics	Hera BioLabs	Pairwise
Symbol
MSH ID	COM:RECOMBINETICS	COM:HERABIOLABS	COM:PAIRWISE
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Consumer Goods
Industry	Biotechnology	Biotechnology	Food & Agriculture
Country	US	US	US
Stage		Venture Round
Employee Count			168
Website	recombinetics.com	herabiolabs.com	pairwise.com
LinkedIn	recombinetics-inc.		pairwise-plants
Founders

Metric
Market Cap		205M
Enterprise Value
Monthly Web Traffic	1.41K	7.21K
Web Traffic Growth	-0.46	0.63
Valuation
Raised Capital	1.07M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

RECO

COM:RECOMBINETICS

Recombinetics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue